Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented new preclinical data from its immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, showcasing promising results for two candidates: TNX-1700 and TNX-4700. The data were featured in one oral and two poster sessions, highlighting the company's progress in developing novel cancer immunotherapies.
TNX-1700, a potential therapy for gastric cancer, demonstrated the ability to reduce inflammation and tumor progression in preclinical models. Additionally, the candidate showed favorable pharmacokinetics, suggesting it could be effectively administered in a clinical setting. Gastric cancer remains a significant unmet medical need, with limited treatment options for advanced stages, making these findings particularly relevant for patients and healthcare providers.
TNX-4700, a candidate targeting BTLA (B- and T-lymphocyte attenuator), exhibited promising in vitro activity. BTLA is an immune checkpoint receptor that inhibits T-cell activation, and targeting it could enhance anti-tumor immune responses. The data suggest TNX-4700 has potential as a standalone immunotherapy or in combination with other checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4 agents, potentially broadening the therapeutic arsenal against various cancers.
These findings underscore Tonix's commitment to advancing its immuno-oncology pipeline, which complements its established focus on central nervous system (CNS) and immunology treatments. The company's CNS portfolio includes TONMYA, a recently approved treatment for fibromyalgia, and other candidates for major depressive disorder, acute stress disorder, and Prader-Willi syndrome. In immunology, Tonix is developing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection prevention.
The implications of these preclinical data are significant for the biotechnology industry and cancer research. If validated in clinical trials, TNX-1700 could offer a new treatment option for gastric cancer patients, while TNX-4700 could contribute to the growing field of combination immunotherapies. For Tonix, positive results could expand its pipeline and potentially lead to partnerships or licensing opportunities. Investors and industry observers will be watching for further developments as the company moves these candidates toward clinical trials.
For more information, visit the company's newsroom at https://ibn.fm/TNXP.
